[1] [1] ROBINSON J P. Spectral flow cytometry-Quo vadimus?[J]. Cytometry A, 2019, 95(8): 823-824.

[2] [2] ROBINSON J P. Flow cytometry: past and future[J]. Biotechniques, 2022, 72(4): 159-169.

[3] [3] WANNER N, BARNHART J, APOSTOLAKIS N,et al. Using the autofluorescence finder on the Sony ID7000 (TM) spectral cell analyzer to identify and unmix multiple highly autofluorescent murine lung populations[J]. Frontiers in Bioengineering and Biotechnology, 2022, 10: 827987.

[4] [4] NOLAN J P. The evolution of spectral flow cytometry[J]. Cytometry A, 2022, 101(10): 812-817.

[6] [6] SAHIR F, MATEO J M, STEINHOFF M,et al. Development of a 43 color panel for the characterization of conventional and unconventional T-cell subsets, B cells, NK cells, monocytes, dendritic cells, and innate lymphoid cells using spectral flow cytometry[J]. Cytometry A, 2020, 105(5): 404-410.

[7] [7] ZACHARIAS Z R, HOUTMAN J C D. OMIP-099: 31-color spectral flow cytometry panel to investigate the steady-state phenotype of human T cells[J]. Cytometry A, 2024, 105(1): 10-15.

[8] [8] BRANDI J, WIETHE C, RIEHN M,et al. OMIP-93: a 41-color high parameter panel to characterize various co-inhibitory molecules and their ligands in the lymphoid and myeloid compartment in mice[J]. Cytometry A, 2023, 103(8): 624-630.

[9] [9] NG H H M, LEE R Y, GOH S,et al. Immunohistochemical scoring of CD38 in the tumor microenvironment predicts responsiveness to anti-PD-1/PD-L1 immunotherapy in hepatocellular carcinoma[J]. Journal for Immunotherapy of Cancer, 2020, 8(2): e000987.

[10] [10] BAUMAN J E, OHR J, GOODING W E,et al. Phase I study of ficlatuzumab and cetuximab in cetuximab-resistant, recurrent/metastatic head and neck cancer[J]. Cancers (Basel), 2020, 12(6): 1537.

[11] [11] MUKHERJEE S, LANFREDINI S, COX C,et al. Translational analysis from SCALOP trial: CCL5 as a prognostic biomarker and a potentially actionable target in locally advanced pancreatic cancer (LAPC)[J]. Journal of Clinical Oncology, 2020, 38: 740-740.

[12] [12] JOHNSON A M, BULLOCK B L, NEUWELT A J,etal. Cancer cell-intrinsic expression of MHC Class II regulates the immune microenvironment and response to anti-PD-1 therapy in lung adenocarcinoma[J]. Journal of Immunology, 2020, 204(8): 2295-2307.

[13] [13] YANG M, DU W, YI L,et al. Checkpoint molecules coordinately restrain hyperactivated effector T cells in the tumor microenvironment[J]. Oncoimmunology, 2020, 9(1): 1708064.

[14] [14] HE Y, KOCH R, BUDAMAGUNTA V,et al. DT2216: a Bcl-xL-specific degrader is highly active against Bcl-xL-dependent T cell lymphomas[J]. Journal of Hematology & Oncology, 2020, 13(1): 95.

[15] [15] ZHANG X, THUMMURI D, LIU X,et al. Discovery of PROTAC Bcl-xL degraders as potent anticancer agents with low on-target platelet toxicity[J]. European Journal of Medicinal Chemistry, 2020, 192: 112186.

[16] [16] CAROZZA J A, BOHNERT V, NGUYEN K C,et al. Extracellular cGAMP is a cancer cell-produced immunotransmitter involved in radiation-induced anti-cancer immunity[J]. Nature Cancer, 2020, 1(2): 184-196.

[17] [17] SI Y, TIAN Q, ZHAO F,et al. Adjuvant-free nanofiber vaccine inducesin situlung dendritic cell activation and TH17 responses[J]. Science Advances, 2020, 6(32): eaba0995.

[18] [18] DENAULT K A, CANTORE M, NAKAMURA S,et al. Efficient and stable laser-driven white lighting[J]. Aip Advances, 2013, 3(7): 072107.

[19] [19] GEORGE A F, AL-WAISAWY S, WRIGHT J T,et al. Laser-driven phosphor-converted white light source for solid-state illumination[J]. Applied Optics, 2016, 55(8): 1899-1905.

[20] [20] KNIGHT J C, BIRKS T A, RUSSELL P S J,et al. All-silica single-mode optical fiber with photonic crystal cladding: errata[J]. Optics Letters, 1997, 22(7): 484-485.